By Dennis Thompson HealthDay ReporterWEDNESDAY, Jan. 7, 2026 (HealthDay News) — Surgery should be a last resort for people ...

A new clinical practice update outlines a stepwise approach to diagnosing and managing refractory constipation before ...

A new update from the American Gastroenterological Association (AGA) is calling for greater caution before surgery is ...

The highest overall response rate (ORR) was observed in patients treated with the lowest dose of axatilimab at 0.3 mg/kg every 2 weeks, with an ORR of 74% (95% CI 63-83) within the first 6 months, ...

For over 60 years, the search for an effective pharmacologic treatment for refractory or unexplained chronic cough has been ...

Primary end point was met, with overall response for 74, 67, and 50% receiving axatilimab 0.3-, 1-, and 3mg per kilogram of body weigh HealthDay News — For patients with recurrent or refractory ...

The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...

Please provide your email address to receive an email when new articles are posted on . Four of six patients who used sirolimus had positive responses and discontinued systemic corticosteroids. Three ...

Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA ...

Please provide your email address to receive an email when new articles are posted on . Lirentelimab improved disease control among patients with antihistamine-refractory chronic urticaria, according ...

Chronic constipation affects 8–12% of Americans. While most patients improve with conventional treatments, a small but ...